1 / 3
Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeutics to address unmet clinical needs in the world.
Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization.
Ribo strives innovation of key technologies for development of oligonucleotide therapeutics. Our liver-targeting delivery technology and second-generation modification chemistry have been fully developed and supported several products entering clinical phase of development. Moreover, we have made substantial advancement in developing extrahepatic delivery technologies, and we also made commendable achievement in additional fronts, including our third-generation modification chemistry, multi-target siRNA technology, and novel synthetic methodologies.
Through our innovation, Ribo has built a robust pipeline of oligonucleotide therapeutics that focus on differentiated drug product development with the potential to be First-In-Class or Best-In-Class. Our pipeline covers multiple therapeutic areas, including cardiovascular and metabolic disorders, liver diseases and rare diseases.
RBD7022
Hyperlipidemia
RBD5044
Hyperlipidemia
RBD4059
Thromboembolism
RBD1016
HBV
RBD7007
IgA Nephropathy
RBD8088
Glioma
